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To determine whether increased migration is 
associated with an increase in incidence of toxocariasis 
(visceral larva migrans), we analyzed clinical data obtained 
from immigrants from Latin America. Although infection with 
Toxocara sp. roundworm larvae is distributed worldwide, 
seroprevalence is highest in tropical and subtropical areas. 
H
uman toxocariasis is a zoonosis caused by the larvae 
of Toxocara sp. roundworms. Although distribution 
is worldwide, seroprevalence is highest in tropical 
countries, including in Latin America. Immigration from 
tropical areas to Europe continues to increase, with Spain 
a frequent destination. Data on visceral larva migrans 
(VLM) among immigrants from Latin America in western 
countries (primarily European countries, the United States, 
and Canada) are scarce. To determine whether increased 
migration is associated with increased VLM incidence, we 
analyzed clinical and epidemiologic data from immigrants 
from Latin America.
The Study
We analyzed information about 634 immigrants from 
Latin America seen at the Tropical Medicine Unit of the 
Ramón y Cajal Hospital in Madrid, Spain, during April 
1989–June 2008. Immigrants who were visiting friends 
and relatives were excluded. Patients with VLM were 
identiﬁ  ed.
We used 5 strict criteria for diagnosing VLM: 1) 
positive serologic test for Toxocara sp. roundworm 
infection, performed by using a commercial ELISA 
Toxocara immunoglobulin (Ig) G Ridascreen (R-Biopharm 
GmbH, Darmstadt, Germany), following the manufacturer’s 
recommendations; 2) absolute peripheral blood eosinophil 
count >500 cells/mm3; 3) exclusion of other parasites causing 
eosinophilia, such as intestinal nematodes, particularly 
Strongyloides stercoralis (excluded by larval culture 
and serology by ELISA IgG), Schistosoma sp.,  Fasciola 
hepatica, Trichinella spiralis, Taenia solium, Echinococcus 
granulosus, and cutaneous and blood microﬁ  lariae; 
4) symptoms associated with VLM (respiratory signs, 
such as asthma, dyspnea, and eosinophilic pneumonia; 
dermatologic symptoms, including pruritus and recurrent 
urticaria; and abdominal symptoms, including abdominal 
pain and hepatomegaly); and 5) response to treatment 
with albendazole (10–15 mg/kg/d in 2 doses orally for 5 
days) assessed 6 months after treatment, decreased titers to 
Toxocara sp. roundworm infection, decreased eosinophil 
count, and clinical improvement or resolution of symptoms.
The most frequent countries of origin for patients were 
Ecuador 221/634 (34.9%), Bolivia 176/634 (27.8%), Peru 
71/634 (11.2%), and Colombia 56/634 (8.8%). Median 
age was 32 years (range 4–40 years); 421 (66.4%) patients 
were male. The median number of months from arrival in 
Spain to ﬁ  rst consultation at the Tropical Medicine Unit 
was 19 months.
Eosinophilia was present in 135 (21.3%) patients. 
Toxocara antibodies were detected by ELISA in 31 
(4.9%) patients. Concomitant serologic results positive 
for  Toxocara sp. roundworm infection and eosinophilia 
were found in 28 (4.4%) patients; 606 patients were 
excluded. Of these 28 patients, 11 were excluded because 
of other concomitant parasitic infections that also can cause 
eosinophilia: 8 patients had positive ELISA results for S. 
stercoralis nematodes (not detected in fecal samples or 
larval culture); 1 had Ascaris lumbricoides eggs in feces; 1 
had a positive indirect hemagglutination result but negative 
ELISA result for E. granulosus tapeworm; and 1 had a 
positive ELISA serologic result for T. spiralis nematodes. 
Another 12 patients were not included because detection 
of Strongyloides antibodies was not attempted. Only 4 of 
the 5 remaining cases fulﬁ  lled the strict inclusion criteria 
(Table); 1 patient was asymptomatic. After 6 months 
of treatment with albendazole, titers for Toxocara sp. 
roundworm infection and eosinophil count decreased, 
and symptoms improved or resolved for the 4 patients. 
Symptoms developed 3–18 months after arrival in Spain.
Clinical toxocariasis is rarely diagnosed in western 
countries as previously described despite evidence of 
environmental exposure (1). Results o  f seroprevalence 
surveys performed in healthy adults in France were positive 
for 2%–5% of persons in urban areas, compared with 14%–
37% in rural areas (2). In Latin America, rates vary from 
1.8% to 51.6% (3,4). However, literature references to VLM 
imported by immigrants are scarce (5), and the disease may 
be underdiagnosed in the immigrant population, partly 
because of nonspeciﬁ  c symptoms and the limitations of 
serologic diagnosis. In our study, serologic prevalence of 
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Toxocariasis is a common cause of eosinophilia in 
peripheral blood, although its absence does not exclude 
infection by Toxocara sp. roundworms. In other studies, 
27% of patients had reactive serologic results for Toxocara 
sp. roundworm infection without eosinophilia (6); similarly, 
27% of patients with high antibody titers had eosinophil 
counts within the reference range (7). By including only 
patients with eosinophilia, our study applied more stringent 
criteria. Thus, 28 (90%) of 31 patients who had positive 
serologic results showed an elevated eosinophil count, 
in accordance with previously described high Toxocara 
sp. roundworm seroprevalence (<68%) in patients with 
eosinophilia of unknown cause (8).
Eleven of the 28 patients with positive serologic 
results for Toxocara sp. roundworm and eosinophilia 
also had positive serologic results for other parasites that 
cause eosinophilia. One patient who was infected with 
A. lumbricoides roundworm had asthma, hepatomegaly, 
and pruritus. The latter is not usually associated with this 
parasite, which suggests possible co-infection.
Serologic tests for Toxocara sp. roundworm infection 
should be interpreted with caution because commercial 
ELISA kits that use excretory and secretory antigens 
derived from second-stage larvae of Toxocara sp. 
roundworms exhibit a sensitivity of 91% and a speciﬁ  city 
of 86%; cross-reactivity has also been described with other 
nematode infections. The positive serologic results for 
T. spiralis nematodes and E. granulosus tapeworms may 
have been caused by cross-reactivity (9). These patients 
had asthenia and asthma, respectively, and symptoms 
resolved after treatment with albendazole. Eight patients 
with  Strongyloides antibodies were also excluded; 
however, this ﬁ   nding does not exclude co-infection by 
both parasites. Finally, a limitation of the study was that 
we could not deﬁ  nitively exclude cryptic strongyloidiasis 
for 12 patients because of the difﬁ  culty  in  ﬁ  nding  S. 
stercoralis threadworms in feces and because detection of 
Strongyloides antibodies was not possible.
Other authors have already recommended caution 
when interpreting positive Toxocara sp. roundworm 
serologic results in asymptomatic persons or persons with 
equivocal symptoms (10). Therefore, the asymptomatic 
patient with positive serologic and eosinophilia results was 
also excluded.
This study illustrates the difﬁ   culties in diagnosing 
VLM in immigrants from tropical and subtropical areas 
of Latin America because only a very small proportion of 
patients in the series (n = 4) had VLM. The most common 
symptoms were respiratory (3/4); 2 patients had asthma-
like syndrome and 1 had chest pain followed by abdominal 
pain (2/4). Typical manifestations of VLM are abdominal 
symptoms (pain, hepatomegaly) and respiratory symptoms 
(severe asthma, eosinophilic inﬁ  ltrates). In addition to this, 
evidence points to Toxocara sp. roundworm infection as a 
risk factor for asthma in some populations (11,12).
Albendazole is the treatment of choice for VLM; 
for practical purposes, it could be recommended for 
presumptive treatment in immigrants from Latin America 
with eosinophilia in whom strongyloidiasis is suspected 
(13). However, the superiority of ivermectin over 
albendazole has been documented in the treatment of 
chronic strongyloidiasis (14).
Conclusions
VLM may be difﬁ   cult to diagnose, especially 
in immigrants from regions in Latin America where 
polyparasitism is endemic. Positive serologic test 
results, marked eosinophilia, absence of other helminthic 
infections, compatible clinical signs, and disappearance 
of symptoms after speciﬁ  c treatment can help establish 
a VLM diagnosis, especially in areas of low parasitism. 
VLM should be included in the differential diagnosis of 
eosinophilia in immigrants (children and adults) from 
tropical areas if respiratory or abdominal symptoms are 
evident. Albendazole is an effective and relatively safe 
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Table. Descriptions of 4 cases of visceral larva migrans in immigrants from Latin America, Spain, April 1989–June 2008* 
Case
no.
Age,
y/sex Origin 
Clinical signs and 
symptoms 
Chest radiograph 
results 
Eosinophil count, 
absolute/mm
3 (%) 
6-mo follow-up 
Eosinophil
count/mm
3
Decrease in 
antibody titers Symptoms
1 28/M Bolivia Asthma-like 
syndrome† 
Slight right 
parahiliar infiltrate
700 (17.0)  500  Yes   None
2 29/F Dominican
Republic
Dry cough, dyspnea, 
chest pain, 
eosinophilic
pneumonia
Bilateral alveolar 
infiltrates 
1,400 (10.5)  600  Yes   None
3 5/F Ecuador Asthma-like 
syndrome, 
abdominal pain
No findings  1,050 (15.0)  700  Yes   None
4 40/F Colombia Abdominal pain  Not done 1,500 (14.8)  400  Yes   Clinical
improvement
*All patients were treated with albendazole (10–15 mg/kg/d in 2 doses orally for 5 days). 
†Wheezing and dry cough. Visceral Larva Migrans from Latin America
drug that could be used to treat suspected VLM and other 
concomitant nematode infections, including cryptic S. 
stercoralis threadworm infections. Empirically described 
treatment may lead to resolution of clinical symptoms, 
even though ivermectin is a better treatment for chronic 
strongyloidiasis. 
The Red de Investigación de Centros de Enfermedades 
Tropicales (RED: RD06/0021/0020) provided funding for this 
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